{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T04:06:27Z","timestamp":1784261187860,"version":"3.55.0"},"reference-count":21,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Cytotoxic cutaneous T-cell lymphomas (CTCLs) are a heterogeneous group of T-cell lymphomas with variable prognoses and no standard of care. We identified patients with primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma (CD8+ PCAETL), primary cutaneous \u03b3\u03b4 T-cell lymphoma (PCGDTL), and subcutaneous panniculitis-like T-cell lymphoma (SPTCL), who were treated with \u22651 dose of pralatrexate between 2015 and 2024 at the University of Washington\/Fred Hutchinson Cancer Center. Eighteen patients met criteria, 3 with CD8+ PCAETL, 6 with PCGDTL, and 9 with SPTCL. The median number of prior systemic therapies was 1 (range, 0-4), and the median pralatrexate treatment duration was 14 (range, 8-43) weeks. The overall response rate was 100%, with 12 (67%) achieving complete response (CR). Median duration of progression-free survival and overall survival was 5.6 months and not reached, respectively. Among patients who achieved CR , the median response duration was 22 months. At a median follow-up of 45 months, 6 (33%) patients remain in sustained remission. This retrospective analysis is the first to evaluate pralatrexate\u2019s efficacy in this aggressive disease population, demonstrating its effectiveness and association with durable responses in cytotoxic CTCL.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025016680","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:11:06Z","timestamp":1750173066000},"page":"4037-4042","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Pralatrexate is effective in cytotoxic cutaneous T-cell lymphomas"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3120-712X","authenticated-orcid":false,"given":"Christina","family":"Poh","sequence":"first","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna M.","family":"Voutsinas","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6703-0894","authenticated-orcid":false,"given":"Ryan C.","family":"Lynch","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9570-2755","authenticated-orcid":false,"given":"Edus H.","family":"Warren","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitlin A.","family":"Crimp","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"3Department of Dermatology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Till","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1977-1510","authenticated-orcid":false,"given":"Chaitra S.","family":"Ujjani","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6165-2617","authenticated-orcid":false,"given":"Mengyang","family":"Di","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikram","family":"Raghunathan","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5354-7593","authenticated-orcid":false,"given":"Stephen D.","family":"Smith","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-4816","authenticated-orcid":false,"given":"Qian V.","family":"Wu","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1388-5330","authenticated-orcid":false,"given":"Michi M.","family":"Shinohara","sequence":"additional","affiliation":[{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"3Department of Dermatology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"1Division of Hematology and Medical Oncology, University of Washington, Seattle, WA"},{"name":"2Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"issue":"20","key":"2025081210063613600_bib1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2025081210063613600_bib2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.mpdhp.2016.04.004","article-title":"Unusual variants of mycosis fungoides","volume":"22","author":"Virmani","year":"2016","journal-title":"Diagn Histopathol"},{"issue":"2","key":"2025081210063613600_bib3","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood-2007-04-087288","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases","volume":"111","author":"Willemze","year":"2008","journal-title":"Blood"},{"issue":"16","key":"2025081210063613600_bib4","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas [published correction appears in Blood. 2019;134(13):1112]","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"issue":"1","key":"2025081210063613600_bib5","doi-asserted-by":"crossref","first-page":"5","DOI":"10.21037\/cco.2018.11.01","article-title":"Cutaneous T-cell lymphoma (CTCL), rare subtypes: five case presentations and review of the literature","volume":"8","author":"Geller","year":"2019","journal-title":"Chin Clin Oncol"},{"issue":"9","key":"2025081210063613600_bib6","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1182\/blood-2002-05-1597","article-title":"Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma","volume":"101","author":"Toro","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2025081210063613600_bib7","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/j.jaad.2018.05.1243","article-title":"Subcutaneous panniculitis-like T-cell lymphoma: clinical features, therapeutic approach, and outcome in a case series of 16 patients","volume":"79","author":"L\u00f3pez-Lerma","year":"2018","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2025081210063613600_bib8","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"O'Connor","year":"2011","journal-title":"J Clin Oncol"},{"issue":"11","key":"2025081210063613600_bib9","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/j.clml.2018.06.020","article-title":"Clinical activity of pralatrexate in patients with cutaneous T-cell lymphoma treated with varying doses of pralatrexate","volume":"18","author":"Foss","year":"2018","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"18","key":"2025081210063613600_bib10","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1182\/blood-2011-11-390211","article-title":"Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma","volume":"119","author":"Horwitz","year":"2012","journal-title":"Blood"},{"issue":"4","key":"2025081210063613600_bib11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.clml.2012.01.010","article-title":"Pralatrexate is an effective treatment for relapsed or refractory transformed mycosis fungoides: a subgroup efficacy analysis from the PROPEL study","volume":"12","author":"Foss","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"2025081210063613600_bib12","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood.2021012057","article-title":"Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC","volume":"140","author":"Olsen","year":"2022","journal-title":"Blood"},{"issue":"27","key":"2025081210063613600_bib13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025081210063613600_bib14","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1038\/sj.bjc.6601118","article-title":"Survival analysis part I: basic concepts and first analyses","volume":"89","author":"Clark","year":"2003","journal-title":"Br J Cancer"},{"issue":"4","key":"2025081210063613600_bib15","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0197-2456(96)00075-X","article-title":"A note on quantifying follow-up in studies of failure time","volume":"17","author":"Schemper","year":"1996","journal-title":"Control Clin Trials"},{"issue":"2","key":"2025081210063613600_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaad.2019.07.021","article-title":"Pralatrexate for refractory or recurrent subcutaneous panniculitis-like T-cell lymphoma with hemophagocytic syndrome","volume":"82","author":"Ware","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"2025081210063613600_bib17","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1158\/1078-0432.CCR-16-2064","article-title":"Results from a phase I\/II open-label, dose-finding study of pralatrexate and oral bexarotene in patients with relapsed\/refractory cutaneous T-cell lymphoma","volume":"23","author":"Duvic","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2025081210063613600_bib18","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.clml.2014.01.010","article-title":"Pralatrexate alone or in combination with bexarotene: long-term tolerability in relapsed\/refractory mycosis fungoides","volume":"14","author":"Talpur","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"11","key":"2025081210063613600_bib19","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.3109\/10428194.2013.779688","article-title":"Preemptive leucovorin administration minimizes pralatrexate toxicity without sacrificing efficacy","volume":"54","author":"Koch","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025081210063613600_bib20","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1080\/10428194.2019.1612061","article-title":"Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate","volume":"60","author":"Foss","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"suppl 1","key":"2025081210063613600_bib21","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1182\/blood-2018-99-119684","article-title":"Management of mucositis with the use of leucovorin as adjunct to pralatrexate in treatment of peripheral T-cell lymphomas (PTCL) \u2014 results from a prospective multicenter phase 2 clinical trial","volume":"132","author":"Shustov","year":"2018","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/4037\/2405319\/blooda_adv-2025-016680-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/15\/4037\/2405319\/blooda_adv-2025-016680-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:00:12Z","timestamp":1755010812000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/15\/4037\/537799\/Pralatrexate-is-effective-in-cytotoxic-cutaneous-T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":21,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025016680","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,8,12]]},"published":{"date-parts":[[2025,8,4]]}}}